Induction treatment of light chain deposition disease with bortezomib: Rapid hematological response with persistence of renal involvement

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 330-331

  Minarik, Jiri ^a   Scudla, Vlastimil ^a   Tichy, Tomas ^a   Pika, Tomas ^a   Bacovsky, Jaroslav ^a   Lochman, Pavel ^a   Zadrazil, Josef ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE;

ADULT; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DIARRHEA; FEVER; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FIBROSIS; LABORATORY TEST; LETTER; LIGHT CHAIN; LIGHT CHAIN DEPOSITION DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PLASMA CELL DYSCRASIA; PNEUMONIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROTEINURIA; PYRAZINES; REMISSION INDUCTION;

EID: 84856085866     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.619610     Document Type: Letter

References (9)

1. Solomon A, Weiss DT, Herrera GA. Light chain deposition disease In: Mehta J, Singhal S, editors. Myeloma. London: Martin Dunitz; 2002. pp 507-518.
2. Heilman HR, Velosa JA, Holley KE, et al. Long term follow-up and response to chemotherapy in patients with light chain deposition disease. Am J Kidney Dis 1992;20:34-41.
3. Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathology-driven therapy. Clin J Am Soc Nephrol 2006;1:1342-1350.
4. Hassoun H, Flombaun C, D' A gati VD, et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008;42:405-412.
5. Weichman K, Dember LM, Prokaeva T, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339-343.
6. Kastritis E, Migkou M, Gavriatopoulou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2008;94:300-302.
7. Kaposztas Z, Kahan BD, Katz SM, et al. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc 2009;41:4407-4410.
8. Gasparetto C, Sanchorawala V, Snyder RM, et al. Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis. J Clin Oncol 2010;28(15 Suppl.): Abstract 8024.
9. Gharwan H, Truica C. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol 2011 Apr 9. [Epub ahead of print]